Tempest Therapeutics Financials - Benzinga

Tempest Therapeutics Inc

TPSTNASDAQ

Trade with Public

Trade with Public

$0.8500

-0.072-7.81%

À la clôture: Sep 23, 5:00 PM EST

$0.8600

-0.062-6.72%

Pré-ouverture: 4:14 AM EST

Aperçu Actualités Prévisions de résultats Événements Objectifs de coursDonnées financièresSentiment Actionnariat Comparer Rapport sur les stocks

Tempest Therapeutics Financials

Tempest Therapeutics (TPST) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Tempest Therapeutics Q2 EPS $(0.34) Misses $(0.30) Estimate

Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.30) by 13.33 percent. This is a 83.57 percent increase over losses of $(2.07) per

Benzinga Newsdesk

PRO
Tempest Therapeutics Q1 Adj. EPS $(0.50) Misses $(0.28) Estimate

Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.28) by 78.57 percent. This is a 84.18 percent increase over losses of $(3.16) per share

Benzinga Newsdesk

PRO
Tempest Therapeutics Q4 EPS $(0.62) Beats $(3.52) Estimate

Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(3.52) by 82.39 percent. This is a 87.77 percent increase over losses of $(5.07) per share

Benzinga Newsdesk

Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results

Avi Kapoor

Nasdaq Gains Over 100 Points; Target Trims Earnings Forecast

Avi Kapoor

PRO
Tempest Therapeutics Q3 EPS $(0.79) Beats $(3.27) Estimate

Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(3.27) by 75.84 percent. This is a 85.15 percent increase over losses of $(5.32) per share

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved